NEW YORK (GenomeWeb) – Response Genetics today said it has executed a commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University to launch a next-generation sequencing-based lung cancer panel.

The Knight Diagnostic-developed panel provides "full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots," Response Genetics said. It added that it expects to market the panel immediately.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.